miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway

Kailin Xing, Xinyu Bian, Dongmin Shi, Shuangshuang Dong, Hongxin Zhou, Shuxiu Xiao, Jinjin Bai, Weizhong Wu · 2023

Read miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway by Kailin Xing, Xinyu Bian, Dongmin Shi, Shuangshuang Dong, Hongxin Zhou, Shuxiu Xiao, Jinjin Bai, Weizhong Wu (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710742.txt.

Description

Kailin Xing and co-authors report a 2023 study on liver cancer cell death. Ferroptosis is an iron-driven cell death that cancer cells can resist. Highly invasive liver cancer cells resist it more, the team found. Their lipid reactive oxygen levels run low. A small RNA called miR-612 is the focus. The RNA was already known to curb invasion in this cancer through a lipid enzyme.

Cells engineered with extra miR-612 died more readily under a ferroptosis drug. The RNA raised lipid reactive oxygen in the cells. Its action runs through the mevalonate pathway, a cholesterol-building route. Blocking that route is part of how the sensitization works. Cancer teams get a pairing idea: raise this RNA's effect and ferroptosis drugs bite harder. Metastatic cells' resistance is the target, which is where liver cancer kills.

Catalog record

CREATORKailin Xing, Xinyu Bian, Dongmin Shi, Shuangshuang Dong, Hongxin Zhou, Shuxiu Xiao, Jinjin Bai, Weizhong Wu
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10710742

Browse the full library · About the Tower of Babel